Early treatment correlates with better immune fitness, marked by higher CD4-positive naive T cells and a favorable tumor microenvironment. Cilta-cel therapy shows improved outcomes in earlier ...
The 2-year event-free survival (EFS) rate in the treatment arm was 76.3% (95% CI, 61.1%-86.1%), and the 2-year overall survival (OS) rate was 82.0% (95% CI, 67.1%-90.6%). These results showed that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback